Showing results (131-140 of 274) with videos related to

Sort By:
Pageof 28
Blood|April 27, 1999
Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemiaM V Relling, M L Hancock, J M Boyett, et al.
Cancer Treatment Reports|June 1, 1983
Cisplatin-induced changes in bleomycin eliminationG C Yee, W R Crom, J E Champion, et al.
Arthritis and Rheumatism|December 1, 1991
Aspirin alters methotrexate disposition in rheumatoid arthritis patientsC F Stewart, R A Fleming, B F Germain, et al.
Annals of Neurology|December 1, 1994
High-dose dextromethorphan in amyotrophic lateral sclerosis: phase I safety and pharmacokinetic studiesD Hollander, J Pradas, R Kaplan, et al.
Drug Intelligence & Clinical Pharmacy|June 1, 1982
Clinical pharmacology of bleomycin and cisplatinW E Evans, G C Yee, W R Crom, et al.
Head & Neck Surgery|November 1, 1981
Clinical pharmacology of bleomycin and cisplatinW E Evans, G C Yee, W R Crom, et al.
Gene|April 18, 2000
Molecular cloning of a novel human UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase, GalNAc-T8, and analysis as a candidate autosomal dominant hypophosphatemic rickets (ADHR) geneK E White, B Lorenz, W E Evans, et al.
Clinical Pharmacokinetics|May 1, 1980
A model for dosing gentamicin in children and adolescents that adjusts for tissue accumulation with continuous dosingW E Evans, R H Taylor, S Feldman, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1982
Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancerW E Evans, J A Sinkule, W R Crom, et al.
Leukemia & Lymphoma|June 1, 1995
Favorable pharmacodynamic features and superior anti-leukemic activity of B43 (anti-CD19) immunotoxins containing two pokeweed antiviral protein molecules covalently linked to each monoclonal antibody moleculeD E Myers, Y Yanishevski, E Masson, et al.
Pageof 28